Last reviewed · How we verify
INM-176
INM-176 is a small molecule that targets the SGLT2 receptor.
INM-176 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | INM-176 |
|---|---|
| Also known as | KR-WAP-026 |
| Sponsor | Whanin Pharmaceutical Company |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, INM-176 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA (PHASE1, PHASE2)
- AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients (PHASE1)
- An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- INM-176 CI brief — competitive landscape report
- INM-176 updates RSS · CI watch RSS
- Whanin Pharmaceutical Company portfolio CI